Is rosiglitazone associated with increased risk for cardiovascular events? Commentary

Nature Clinical Practice Cardiovascular Medicine

Volumn 4, Issue 12, 2007, Pages 648-649

  Hanefeld, Markolf ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; GLUCOSE; INSULIN; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SULFONYLUREA;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMORBIDITY; DISEASE COURSE; DRUG APPROVAL; DRUG EFFECT; DRUG FATALITY; FOOD AND DRUG ADMINISTRATION; HEART INFARCTION; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; MONITORING; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SHORT SURVEY;

EID: 36448964472     PISSN: 17434297     EISSN: 17434300     Source Type: Journal    
DOI: 10.1038/ncpcardio1030     Document Type: Short Survey

References (5)

1. Marx N (2002) PPARγ and vascular inflammation: Adding another piece to the puzzle. Circ Res 91: 373-374
2. Gerstein HC et al. for the DREAM Trial Investigators (2006) Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomized controlled trial. Lancet 368: 1096-1105
3. Kahn SE et al. for the ADOPT Study Group (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355: 2427-2443
4. Home P et al. for the RECORD Study Group (2007) Rosiglitazone evaluated for cardiovascular outcomes an interim analysis. N Engl J Med 357: 28-38
5. Mohan V and Joshi SR (2007) The rosiglitazone controversy: The Indian perspective. J Assoc Physicians India 55: 477-480